Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
NRX PharmaceuticalsFRA:B1Q +5.42%33 Buyback Yield % is -5.75 as of Jul. 23, 2026. GuruFocus rates FRA:B1Q with a GF Score™ of 33/100. The stock has 4 warning signs investors should review. Among 739 Biotechnology companies, NRX Pharmaceuticals ranks better than 57.65% on this metric.
Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.
NRX Pharmaceuticals Buyback Yield % Historical Data
* Premium members only.
The historical data trend for NRX Pharmaceuticals's Buyback Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:B1Q vs CRBP, PRQR, TNYA: Buyback Yield % Comparison
For the Biotechnology subindustry, NRX Pharmaceuticals's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
NRX Pharmaceuticals Buyback Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, NRX Pharmaceuticals's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where NRX Pharmaceuticals's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NRX Pharmaceuticals (FRA:B1Q) has a Buyback Yield % of -5.75 as of Jul. 23, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on NRX Pharmaceuticals and its competitors. According to the industry distribution chart, NRX Pharmaceuticals ranks #313 out of 739 companies in the Biotechnology industry, placing it in the top 42.4%.
Is NRX Pharmaceuticals' Buyback Yield % too high?
NRX Pharmaceuticals' current Buyback Yield % is -5.75. Based on the distribution chart, NRX Pharmaceuticals ranks #313 out of 739 companies in the Biotechnology industry, which is above the industry midpoint. Overall, NRX Pharmaceuticals has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does NRX Pharmaceuticals' Buyback Yield % compare to CRBP and PRQR?
According to the Biotechnology industry distribution chart, NRX Pharmaceuticals ranks #313 out of 739 companies for Buyback Yield %. This puts NRX Pharmaceuticals in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Biotechnology company?
A good Buyback Yield % depends on the Biotechnology industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on NRX Pharmaceuticals and its competitors. NRX Pharmaceuticals's current Buyback Yield % is -5.75. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NRX Pharmaceuticals stock overvalued right now?
NRX Pharmaceuticals (FRA:B1Q) has a current Buyback Yield % of -5.75. The current Buyback Yield % is -5.75. NRX Pharmaceuticals' overall GF Score™ is 33/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For NRX Pharmaceuticals (FRA:B1Q), the current Buyback Yield % is -5.75 as of Jul. 23, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. The company is developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.
33GF Score
Get the complete analysis for FRA:B1Q
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:B1Q has been successfully added to your 
